End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +1.95% | +1.23% | -31.83% |
06-03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
05-30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
TRISALUS LIFE SCIENCES, INC. | Bio Therapeutic Drugs | +1.95% | +1.23% | -31.83% | -45.61% | - | 150M | - | - | - |
Technical Rankings Surperformance
- Stock Market
- Equities
- TLSI Stock
- Charts TriSalus Life Sciences, Inc.
- Comparison Chart